Related Experiment Video

Updated: May 15, 2025

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

13.2K

Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium

Mengnan Wang1, Benedikt Preckel1, Coert J Zuurbier1

  • 1Department of Anesthesiology - Laboratory of Experimental Intensive Care and Anesthesiology-L.E.I.C.A, Amsterdam University Medical Centers, Amsterdam Cardiovascular Science, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Basic Research in Cardiology
|May 14, 2025
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show promise for heart failure (HF) by improving endothelial function. They protect heart cells by regulating calcium and nitric oxide pathways, reducing inflammation and oxidative stress.

Area of Science:

  • Cardiovascular Disease Research
  • Endothelial Biology
  • Pharmacology

Background:

  • Heart failure (HF) is a critical condition with high mortality and economic impact.
  • Endothelial ion channels are vital for vascular function, regulating Ca2+ signals, tone, inflammation, and oxidative stress.

Purpose of the Study:

  • To review the role of Ca2+-related ion channels in endothelial cells during HF.
  • To explore the protective effects of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) on endothelial function in HF.

Main Methods:

  • Literature review of clinical and preclinical studies on SGLT2i in HF.
  • Focus on the impact of SGLT2i on endothelial ion channels like NHE1 and NCX.
  • Analysis of SGLT2i's effects on nitric oxide pathways, inflammation, and oxidative stress.

Main Results:

  • SGLT2i demonstrate significant cardiovascular benefits in HF patients, reducing mortality and hospitalizations.
  • SGLT2i exert cardioprotective effects by enhancing endothelial nitric oxide (NO) pathways.
  • SGLT2i may protect endothelial cells by reducing intracellular Ca2+ via inhibition of NHE1 and NCX.

Conclusions:

  • SGLT2i offer a promising therapeutic strategy for heart failure, largely through endothelial protection.
  • Targeting endothelial ion channels and calcium signaling represents a key mechanism for SGLT2i's benefits in HF.
  • Further research into SGLT2i's impact on endothelial ion channels can optimize HF treatment.

Keywords:
Endothelial cellsEndothelial dysfunctionHeart failureIon channelsSodium-glucose cotransporter 2 inhibitorsVascular tone

More Related Videos

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

13.3K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

1.7K

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
295
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
426
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K